Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer.
OBJECTIVE
To evaluate the efficacy and toxicity of a combination of irinotecan (CPT-11) and cisplatin as first-line chemotherapy in advanced ovarian cancer.


METHODS
Twenty-six patients with previously untreated advanced epithelial ovarian cancer were enrolled in this study. CPT-11 60 mg/m(2) was administered intravenously on days 1, 8, and 15 in combination with cisplatin 60 mg/m(2) on day 1. Cycles were repeated every 28 days for at least two cycles. The median patient age was 55 years (range, 37-75), and the median performance status was 1.


RESULTS
Objective responses were recorded in 19 of 25 eligible patients (76%; 95% confidence interval, 55-91%). Complete responses were obtained in 2 patients (8%), and partial response in 17 patients (68%). Stable disease was recorded in 2 patients (8%) and progressive disease in 2 (8%). The median time to response was 62 days (range, 28-234 days). The median survival time for all 25 patients was 30.9+ months (range, 4.1-60.0+ months). The major toxic effects were leukopenia, neutropenia, and diarrhea. Grade 3 or 4 leukopenia, neutropenia, and diarrhea occurred in 17 (68%), 20 (83.3%), and 5 patients (20%), respectively. Thrombocytopenia was less common. No treatment-related deaths occurred.


CONCLUSIONS
The combination of CPT-11 and cisplatin showed significant activity in chemotherapy-naive patients with advanced ovarian cancer. Neutropenia was the dose-limiting adverse effect, whereas diarrhea was mainly mild to moderate.
Sugiyama
Toru
T
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume City, Japan. sugisama@med.kurume-u.ac.jp
Yakushiji
Michiaki
M
Kamura
Toshiharu
T
Ikeda
Masanori
M
Umesaki
Naohiko
N
Hasegawa
Kazuo
K
Ishikawa
Mutsuo
M
Saji
Fumitaka
F
Hiura
Masamichi
M
Takahashi
Takeshi
T
Sato
Shinji
S
Ochiai
Kazunori
K
Kikkawa
Fumitaka
F
Takeuchi
Shoshichi
S
Ohashi
Yasuo
Y
Noda
Kiichiro
K
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011446:Prospective Studies; D016896:Treatment Outcome
D000077146:Irinotecan; D002945:Cisplatin; D002166:Camptothecin